IL2 and pancreatic neoplasm: Administration of an Onc.Ad expressing TNFa and IL-2 (Onc.Ad-IL2/TNFa) in five consecutive doses has significant antitumor effect in an immune competent Syrian hamster model of pancreatic cancer (38).